GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval
GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.
How this was made

The 30-second read
Why it matters
The FDA accelerated approval provides a new US revenue stream and de-risks part of the acquisition thesis, but the article emphasizes that first-line expansion is the main value driver and depends on ongoing Phase III results.
Market read
Traders can reassess GSK’s oncology pipeline value after a fresh FDA approval, while monitoring the next catalyst tied to first-line label expansion.
What to watch
The article does not quantify pricing, uptake, or safety profile; investors may need additional data on tolerability versus Alecensa and real-world prescribing behavior.
Background
GSK acquired Nuvalent for $10.6bn mid-July, and Nelkarmi is the second lung-cancer drug to reach market from that portfolio.
Ticker impact
FDA approved GSK’s Nelkarmi (neladalkib) for ALK-positive NSCLC, the second product from its $10.6bn Nuvalent takeover.
Likely positive repricing as investors underwrite incremental revenue from a new FDA-approved ALK inhibitor, tempered by uncertainty around first-line adoption.
The article is a direct FDA approval with trial-based efficacy metrics, while also flagging that first-line expansion depends on ongoing ALKAZAR Phase III results.
Market effects
Reinforces competitive intensity in ALK-positive NSCLC and highlights the importance of CNS penetration and resistance-mutation coverage.
US FDA approval can shift near-term sentiment for global pharma with oncology assets, especially those with US commercialization gaps.
US label expansion expectations can influence global ALK inhibitor competitive positioning and partner/competitor valuation narratives.
Counterpoint
Near-term upside may be limited if Nelkarmi’s uptake stays concentrated in previously treated patients, with first-line adoption delayed by ALKAZAR Phase III outcomes.
Key entities
- companyGSK
British pharma issuer of Nelkarmi, approved by the FDA for ALK-positive NSCLC.
- companyNuvalent
Pipeline source acquired by GSK for $10.6bn; Nelkarmi and Jideytro are products from its portfolio.
- regulatorFDA
Approved Nelkarmi accelerated approval for previously treated ALK-positive NSCLC.
- companyRoche
Alecensa is cited as a main competitor to Nelkarmi.




